CN112237573B - 含finerenone的片剂及其制备方法 - Google Patents
含finerenone的片剂及其制备方法 Download PDFInfo
- Publication number
- CN112237573B CN112237573B CN202011182013.7A CN202011182013A CN112237573B CN 112237573 B CN112237573 B CN 112237573B CN 202011182013 A CN202011182013 A CN 202011182013A CN 112237573 B CN112237573 B CN 112237573B
- Authority
- CN
- China
- Prior art keywords
- finerenone
- parts
- tablet
- coating
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BTBHLEZXCOBLCY-QGZVFWFLSA-N (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide Chemical compound C1([C@@H]2C(=C(C)NC=3C(C)=CN=C(C2=3)OCC)C(N)=O)=CC=C(C#N)C=C1OC BTBHLEZXCOBLCY-QGZVFWFLSA-N 0.000 title claims abstract description 39
- 229950004408 finerenone Drugs 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000011248 coating agent Substances 0.000 claims abstract description 31
- 238000000576 coating method Methods 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 20
- 239000002904 solvent Substances 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 13
- 239000011247 coating layer Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 239000002245 particle Substances 0.000 claims description 24
- 238000002156 mixing Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 14
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 12
- 229920000881 Modified starch Polymers 0.000 claims description 11
- 229920003081 Povidone K 30 Polymers 0.000 claims description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 239000008213 purified water Substances 0.000 claims description 10
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229940069328 povidone Drugs 0.000 claims description 6
- 238000005550 wet granulation Methods 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 abstract description 11
- 239000003795 chemical substances by application Substances 0.000 abstract description 9
- 239000000945 filler Substances 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 239000000853 adhesive Substances 0.000 abstract description 4
- 230000001070 adhesive effect Effects 0.000 abstract description 4
- 239000000314 lubricant Substances 0.000 abstract description 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 238000003756 stirring Methods 0.000 description 14
- 238000009472 formulation Methods 0.000 description 12
- 238000010008 shearing Methods 0.000 description 10
- 239000000843 powder Substances 0.000 description 8
- 229960000913 crospovidone Drugs 0.000 description 6
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 6
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 229960001208 eplerenone Drugs 0.000 description 4
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 4
- 229960002256 spironolactone Drugs 0.000 description 4
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 229960001681 croscarmellose sodium Drugs 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 229960000502 poloxamer Drugs 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 2
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 2
- 229940083712 aldosterone antagonist Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002394 mineralocorticoid antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229940122522 Mineralocorticoid antagonist Drugs 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000009507 drug disintegration testing Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及医药制剂技术领域,具体涉及一种含finerenone的片剂及其制备方法。所述含finerenone的片剂,包括药物片芯和包衣层,药物片芯由以下重量份数的原料组成:Finerenone5‑30份,填充剂85‑135份,崩解剂5‑7份,粘合剂5‑7份,增溶剂0.3‑1份,润滑剂0.6‑1.2份;包衣层为水溶性包衣材料。本发明的含finerenone的片剂溶出性能好,稳定性高,并且在各介质下均能实现好的溶出效果,本发明还提供其制备方法。
Description
技术领域
本发明涉及医药制剂技术领域,具体涉及一种含finerenone的片剂及其制备方法。
背景技术
目前使用的醛固酮受体拮抗剂为螺内酯(第1代)、依普利酮(第2代)等。大型临床试验表明,螺内酯和依普利酮可明显改善心衰患者的预后,提高生存率,但选择性低,可能导致患者血钾水平升高等不良反应,人们并未将其作为一线药物使用。Finerenone是第三代醛固酮受体拮抗剂,其结构式如下:
Finerenone以与甾体类盐皮质激素受体拮抗剂不同的方式结合在MR的配体结合域中,并且表现出较高的结合率,抑制50%的受体活化所需的拮抗剂的浓度仅为17.8nm,而螺内酯和依普利酮分别为24nm和990nm;另外finerenone在心脏和肾脏可达到等量的分布,而甾体类盐皮质激素拮抗剂则更多的存在于肾脏中,因此finerenone代表更有效的盐皮质激素受体拮抗剂。目前国内尚未有专利和文献公开与finerenone片剂相关的处方和工艺。
发明内容
本发明的目的在于提供一种含finerenone的片剂,同时提供能生产出一种溶出性能好,稳定性高,并且在各介质下均能实现好的溶出的制备方法。
本发明所述的含finerenone的片剂,包括药物片芯和包衣层,药物片芯由以下重量份数的原料组成:
包衣层为水溶性包衣材料。
Finerenone粒度为D50≤35μm,D90≤82μm。
填充剂为微晶纤维素、乳糖、玉米淀粉、预胶化淀粉中的一种或多种;优选微晶纤维素与预胶化淀粉的混合物。
崩解剂为交联聚维酮、交联羧甲基纤维素钠、羧甲基淀粉钠、玉米淀粉中的一种或多种;优选交联聚维酮。
粘合剂为聚维酮K30、羟丙基纤维素、羧甲基纤维素钠中的一种或多种;优选聚维酮K30。
增溶剂为十二烷基硫酸钠、吐温20、泊洛沙姆中的一种或多种;优选十二烷基硫酸钠。
润滑剂为硬脂酸镁、滑石粉、微粉硅胶的一种或多种;优选滑石粉。
包衣层的质量为药物片芯质量的1%-4%。
优选的,所述含finerenone的片剂的药物片芯处方如下:
本发明所述的含finerenone的片剂的制备方法,采用湿法制粒工艺,包括以下步骤:
(1)将finerenone微粉化至粒度为D50≤35μm,D90≤82μm;
(2)将微粉化后的finerenone、粘合剂、增溶剂加入纯化水中制备成颗粒溶液;
(3)将填充剂、崩解剂放入湿法造粒机中,混合均匀,加入颗粒溶液进行制粒;
(4)将制得的颗粒过60目筛整粒,干燥;
(5)将润滑剂和干燥后的颗粒中放入三维混合机中,混合均匀;
(6)将步骤(5)所得物料进行压片,用包衣液包衣,即得含finerenone的片剂。
步骤(2)中,纯化水与finerenone的质量比为15:1-20:1。
步骤(6)中,包衣液由以下重量份数的原料组成:
水溶性包衣材料 5-7份
包衣溶剂 30-60份;
水溶性包衣材料为欧巴代;
包衣溶剂为水、乙醇或水和乙醇的混合物,优选为水和乙醇的混合物,水和乙醇的混合体积比为6:1-1:1。
优选的,所述的含finerenone的片剂的制备方法,包括以下步骤:
(1)将finerenone微粉化至粒度为D50≤35μm,D90≤82μm;
(2)将微粉后的finerenone、粘合剂、增溶剂加入纯化水中制备成颗粒溶液;
(3)将填充剂、崩解剂放入湿法造粒机中,低切低搅10-30min,混合均匀,加入颗粒溶液,低切高搅5-15min,进行制粒;
(4)将制得的颗粒过60目筛整粒,干燥;
(5)将润滑剂和干燥后的颗粒中放入三维混合机中,转速10-30rpm,混合10-30min,混合均匀;
(6)将步骤(5)所得物料加入压片机中压片,压片硬度控制在2-10kg,在包衣设备中用包衣液包衣,即得含finerenone的片剂。
步骤(3)中,低切低搅的搅拌低速为150r/min,剪切低速为1500r/min;低切高搅的搅拌高速为300r/min,剪切低速为1500r/min。
在制备过程中,finerenone需微粉化,使其达到一定的粒度,混合后主药含量更为均匀,制得的片剂更为细腻均匀;其中finerenone的溶出速率也大为加快,同等重量的药物,粒度越小,表面积越大,溶解越快。十二烷基硫酸钠需和微粉后的finerenone、聚维酮K30一起加入纯化水中,制备成颗粒溶液,否者finerenone分布不充分,导致片剂含量均匀度不合格。
与现有技术相比,本发明具有以下有益效果:
(1)本发明制备的含finerenone的片剂,质量稳定,药物疗效和性能指标与原研制剂相似,但价格相较于原研低很多,很大程度的减轻了患者的经济压力;
(2)本发明制备的含finerenone的片剂工艺耐受性好,稳定性高;
(3)本发明制备的含finerenone的片剂,溶出批内均一性较好,生物利用度高。
具体实施方式
下面结合实施例对本发明做进一步说明。
实施例1-4
实施例1-4的药物片芯处方中,finerenone微粉粒度不同,用于考察finerenone微粉粒度对药物溶出度的影响。实施例1-4的药物片芯处方如表1所示。
表1实施例1-4的药物片芯处方
按照上述处方制备含finerenone的片剂,方法如下:
(1)将finerenone微粉化至各实施例相应的粒度;
(2)将微粉后的finerenone、聚维酮K30、十二烷基硫酸钠加入150mg纯化水中制备成颗粒溶液;
(3)将微晶纤维素、预胶化淀粉、交联聚维酮放入湿法造粒机中,低切低搅(低速150r/min,剪切1500r/min)20min,混合均匀,加入颗粒溶液,低切高搅(高速300r/min,剪切1500r/min)10min,进行制粒;
(4)将制得的颗粒过60目筛整粒,干燥;
(5)将滑石粉和干燥后的颗粒中放入三维混合机中,转速20rpm,混合20min,混合均匀;
(6)将步骤(5)所得物料加入压片机中压片,压片硬度控制在6kg,在包衣设备中用包衣液(欧巴代、水、乙醇按质量比1:5:2混合)包衣,控制包衣层质量为药物片芯质量的2%,即得含finerenone的片剂。
对实施例1-4制得的含finerenone的片剂进行溶出试验,具体方法如下:
照中国药典2015版四部通则0931第二法,以水900mL为溶出介质,转速为75r/min,于5,10,15,30,45,60min时取溶液10mL,并同时补充相同温度,相同体积的溶出介质,经微孔滤膜滤过,取续滤液作为供试品溶液。各批次的溶出如表2所示。
表2实施例1-4制得的含finerenone的片剂溶出度测试结果
结论:由溶出结果可知原料药finerenone微粉化至粒度D50≤35μm,D90≤82μm及粒度更细时15分钟累积溶出度>85%,故finerenone粒度为D50≤35μm,D90≤82μ时可以满足溶出要求。
实施例5-8
实施例5-8的药物片芯处方中,填充剂和崩解剂的种类和用量不同,用于考察填充剂和崩解剂对药物崩解时间的影响,实施例5-8的药物片芯处方和药物崩解时间如表3所示。
含finerenone的片剂制备方法如下:
(1)将finerenone微粉化至粒度为D50≤35μm,D90≤82μm;
(2)将微粉后的finerenone、聚维酮K30、十二烷基硫酸钠加入200mg纯化水中制备成颗粒溶液;
(3)将微晶纤维素、预胶化淀粉、崩解剂(交联聚维酮或交联羧甲基纤维素钠)放入湿法造粒机中,低切低搅(低速150r/min,剪切1500r/min)20min,混合均匀,加入颗粒溶液,低切高搅(高速300r/min,剪切1500r/min)10min,进行制粒;
(4)将制得的颗粒过60目筛整粒,干燥;
(5)将滑石粉和干燥后的颗粒中放入三维混合机中,转速20rpm,混合20min,混合均匀;
(6)将步骤(5)所得物料加入压片机中压片,压片硬度控制在6kg,在包衣设备中用包衣液(欧巴代、水、乙醇按质量比1:3.5:3.5混合)包衣,控制包衣层质量为药物片芯质量的3%,即得含finerenone的片剂。
表3实施例5-8的药物片芯处方和药物崩解时间
项目 | 实施例5 | 实施例6 | 实施例7 | 实施例8 |
Finerenone(mg) | 10 | 10 | 10 | 10 |
微晶纤维素(mg) | 78 | 78 | 76 | 83.5 |
预胶化淀粉(mg) | 29.5 | 29.5 | 29.5 | 37 |
交联聚维酮(mg) | 5 | / | 7 | 7 |
交联羧甲基纤维素钠(mg) | / | 5 | / | / |
聚维酮K30(mg) | 6 | 6 | 6 | 6 |
十二烷基硫酸钠(mg) | 0.65 | 0.65 | 0.65 | 0.65 |
滑石粉(mg) | 0.85 | 0.85 | 0.85 | 0.85 |
崩解时间(s) | 111 | 120 | 103 | 129 |
结论:通过对填充剂和崩解剂种类和用量考察,崩解剂优选交联聚维酮,预胶化淀粉用量过多会显著降低崩解速度。
实施例9-12
实施例9-12的药物片芯处方中,增溶剂种类、用量和加入方式不同,用于考察增溶剂对药物崩解时间的影响,实施例9-12的药物片芯处方、增溶剂加入方式和药物崩解时间如表4所示。
含finerenone的片剂制备方法如下:
(1)将finerenone微粉化至粒度为D50≤35μm,D90≤82μm;
(2)将微粉后的finerenone、聚维酮K30、增溶剂(十二烷基硫酸钠或泊洛沙姆)加入170mg纯化水中制备成颗粒溶液;
(3)将微晶纤维素、预胶化淀粉、交联聚维酮、增溶剂(十二烷基硫酸钠)放入湿法造粒机中,低切低搅(低速150r/min,剪切1500r/min)20min,混合均匀,加入颗粒溶液,低切高搅(高速300r/min,剪切1500r/min)10min,进行制粒;
(4)将制得的颗粒过60目筛整粒,干燥;
(5)将滑石粉和干燥后的颗粒中放入三维混合机中,转速30rpm,混合10min,混合均匀;
(6)将步骤(5)所得物料加入压片机中压片,压片硬度控制在6kg,在包衣设备中用包衣液(欧巴代、水、乙醇按质量比1:4:3混合)包衣,控制包衣层质量为药物片芯质量的4%,即得含finerenone的片剂。
表4实施例9-12的药物片芯处方、增溶剂加入方式和药物崩解时间
结论:通过对增溶剂种类、用量及加入方式的考察,增溶剂优选十二烷基硫酸钠,加入方式为和微粉后的finerenone、聚维酮K30一起加入纯化水中制备颗粒溶液,显著提高了崩解速度。
实施例13-14
实施例13-14的药物片芯处方如表5所示。
表5实施例13-14的药物片芯处方
处方 | 实施例13 | 实施例14 |
Finerenone(mg) | 10 | 20 |
微晶纤维素(mg) | 72.2 | 73.2 |
预胶化淀粉(mg) | 35 | 22 |
交联聚维酮(mg) | 6.5 | 7 |
聚维酮K30(mg) | 5 | 6 |
十二烷基硫酸钠(mg) | 0.4 | 0.6 |
滑石粉(mg) | 0.9 | 1.2 |
含finerenone的片剂制备方法如下:
(1)将finerenone微粉化至粒度为D50≤35μm,D90≤82μm;
(2)将微粉后的finerenone、聚维酮K30、增溶剂(十二烷基硫酸钠或泊洛沙姆)加入160mg纯化水中制备成颗粒溶液;
(3)将微晶纤维素、预胶化淀粉、交联聚维酮、增溶剂(十二烷基硫酸钠)放入湿法造粒机中,低切低搅(低速150r/min,剪切1500r/min)20min,混合均匀,加入颗粒溶液,低切高搅(高速300r/min,剪切1500r/min)10min,进行制粒;
(4)将制得的颗粒过60目筛整粒,干燥;
(5)将滑石粉和干燥后的颗粒中放入三维混合机中,转速10rpm,混合20min,混合均匀;
(6)将步骤(5)所得物料加入压片机中压片,压片硬度控制在8kg,在包衣设备中用包衣液(欧巴代、水、乙醇按质量比1:6:1混合)包衣,控制包衣层质量为药物片芯质量的1%,即得含finerenone的片剂。
实施例15
对实施例13制备的含finerenone的片剂进行稳定性试验,方法如下:
(1)将实施例13制备的样品分别放置高温60℃、25℃/RH92.5%,光照(总照度不低于1.2×106Lux·hr)条件下,分别于5d、10d取样,检测,与0d相比较,试验结果如表6所示。
表6实施例13制备的含finerenone的片剂的稳定性测试结果
(2)将实施例13制备的放置40℃±2℃/RH75%±5%条件下,分别于1M、2M、3M、6M取样检测,并与0M结果相比较,试验结果如表7所示。
表7实施例13制备的含finerenone的片剂的稳定性测试结果
结论:本发明的药物组合物在影响因素、加速稳定性试验过程中有关物质、含量结果与0d相比未见明显变化,从而说明本发明所提供的finerenone片剂及其制备方法所制得的产品稳定性较好。
Claims (3)
1.一种含finerenone的片剂,其特征在于:包括药物片芯和包衣层,药物片芯由以下重量份数的原料组成:
Finerenone 10份,
微晶纤维素 65-90份,
预胶化淀粉 20-35份,
交联聚维酮 5.5-6.5份,
聚维酮K30 5.5-6.5份,
十二烷基硫酸钠 0.5-0.8份,
滑石粉 0.7-1.1份;
所述含finerenone的片剂的制备方法采用湿法制粒工艺,包括以下步骤:
(1)将finerenone微粉化至粒度为D50≤35um,D90≤82um;
(2)将微粉化后的finerenone、聚维酮K30、十二烷基硫酸钠加入纯化水中制备成颗粒溶液;
(3)将微晶纤维素、预胶化淀粉、交联聚维酮放入湿法造粒机中,混合均匀,加入颗粒溶液进行制粒;
(4)将制得的颗粒过60目筛整粒,干燥;
(5)将滑石粉和干燥后的颗粒中放入三维混合机中,混合均匀;
(6)将步骤(5)所得物料进行压片,用包衣液包衣,即得含finerenone的片剂。
2.根据权利要求1所述的含finerenone的片剂,其特征在于:包衣层的质量为药物片芯质量的1-4%。
3.根据权利要求1所述的含finerenone的片剂,其特征在于:步骤(6)中,包衣液由以下重量份数的原料组成:
水溶性包衣材料 5-7份,
包衣溶剂 30-60份;
水溶性包衣材料为欧巴代;
包衣溶剂为水、乙醇或水和乙醇的混合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011182013.7A CN112237573B (zh) | 2020-10-29 | 2020-10-29 | 含finerenone的片剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011182013.7A CN112237573B (zh) | 2020-10-29 | 2020-10-29 | 含finerenone的片剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112237573A CN112237573A (zh) | 2021-01-19 |
CN112237573B true CN112237573B (zh) | 2023-12-22 |
Family
ID=74170290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011182013.7A Active CN112237573B (zh) | 2020-10-29 | 2020-10-29 | 含finerenone的片剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112237573B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106795155A (zh) * | 2014-08-01 | 2017-05-31 | 拜耳医药股份有限公司 | 制备(4s)‑4‑(4‑氰基‑2‑甲氧基苯基)‑5‑乙氧基‑2,8‑二甲基‑1,4‑二氢‑1,6‑萘啶‑3‑甲酰胺的方法及其纯化以用作活性药物活性成分 |
US20190262340A1 (en) * | 2016-10-11 | 2019-08-29 | Bayer Pharama Aktiengesellschaft | Combination containing sgc stimulators and mineralocorticoid receptor antagonists |
-
2020
- 2020-10-29 CN CN202011182013.7A patent/CN112237573B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106795155A (zh) * | 2014-08-01 | 2017-05-31 | 拜耳医药股份有限公司 | 制备(4s)‑4‑(4‑氰基‑2‑甲氧基苯基)‑5‑乙氧基‑2,8‑二甲基‑1,4‑二氢‑1,6‑萘啶‑3‑甲酰胺的方法及其纯化以用作活性药物活性成分 |
US20190262340A1 (en) * | 2016-10-11 | 2019-08-29 | Bayer Pharama Aktiengesellschaft | Combination containing sgc stimulators and mineralocorticoid receptor antagonists |
Non-Patent Citations (1)
Title |
---|
Pharmacokinetics, safety and tolerabilityof the novel, selective mineralocorticoidreceptor antagonist finerenone–resultsfrom first-in-man and relativebioavailability studies;Silvia Lentini etal.;《Fundamental & Clinical Pharmacology》;第30卷;第172–184页 * |
Also Published As
Publication number | Publication date |
---|---|
CN112237573A (zh) | 2021-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2554169B1 (en) | Pharmaceutical preparation comprising phenylalanine derivative | |
WO2022012172A1 (zh) | 一种难溶性药物口服缓释组合物及其制备方法 | |
CN111632036B (zh) | 一种替格瑞洛片及其制备方法 | |
CN105412036A (zh) | 依匹哌唑口腔崩解片 | |
CN106539765A (zh) | 一种醋酸阿比特龙片及其制备方法 | |
CN105853383A (zh) | 一种治疗糖尿病性神经病变的药物组合物及其制备方法 | |
CN113827575A (zh) | 一种利伐沙班片剂及其制备方法 | |
CN112237573B (zh) | 含finerenone的片剂及其制备方法 | |
CN109464442B (zh) | 一种沙库巴曲缬沙坦钠药物组合物及其制备方法 | |
CN114748435B (zh) | 一种盐酸多奈哌齐口崩片及其制备方法 | |
CN109125270B (zh) | 一种固体制剂及其制备方法 | |
CN111939137A (zh) | 一种含有阿扎那韦和利托那韦的复方片剂及其制备方法 | |
CN102008469A (zh) | 一种替米沙坦氨氯地平片的制备方法 | |
CN110787144A (zh) | 一种含有氢溴酸伏硫西汀的薄膜包衣片及其制备方法 | |
CN107744509B (zh) | 枸橼酸莫沙必利片剂及其制备方法 | |
CN106749174A (zh) | 一种西他沙星二水合物晶型、制备方法及其组合物片剂 | |
CN104324013A (zh) | 吲达帕胺缓释剂的制备工艺 | |
CN112168796A (zh) | 双相缓释系统控制释放的药物缓释制剂及其制备方法 | |
CN104398482A (zh) | 应用复合乳糖的吲达帕胺缓释药物 | |
CN112206233A (zh) | 一种依鲁替尼口服制剂及其制备方法 | |
CN106474084B (zh) | 一种盐酸普拉克索缓释制剂及其制备方法 | |
CN113768889B (zh) | 一种含西洛他唑的药物组合物及其制备方法 | |
CN117045610B (zh) | 一种溶出高稳定性的盐酸拉贝洛尔组合物及其制备方法 | |
CN112057427A (zh) | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 | |
CN104337783B (zh) | 一种卡培他滨片剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |